Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RFL Stock Forecast 2025-2026
$1.29
Current Price
$66.78M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to RFL Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
RFL Price Momentum
-5.1%
1 Week Change
-3.0%
1 Month Change
-32.8%
1 Year Change
-20.9%
Year-to-Date Change
-59.6%
From 52W High of $3.19
+5.3%
From 52W Low of $1.23
📊 TOP ANALYST CALLS
Did RFL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Rafael Holdings is one of their latest high-conviction picks.
Latest RFL Stock Price Targets & Analyst Predictions
RFL has shown a year-to-date change of -20.9% and a 1-year change of -32.8%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for RFL. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RFL Analyst Ratings
0
Buy
0
Hold
0
Sell
RFL Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $1.29
Latest RFL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RFL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Rafael Holdings Inc. (RFL) Competitors
The following stocks are similar to Rafael Holdings based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
RFL
Rafael Holdings
mkt cap
70.41M
Rafael Holdings Inc. (RFL) Financial Data
Rafael Holdings Inc. has a market capitalization of $66.78M with a P/E ratio of 14.3x. The company generates $917,000 in trailing twelve-month revenue with a 75.8% profit margin.
Revenue growth is +112.1% quarter-over-quarter, while maintaining an operating margin of -3,360.9% and return on equity of -33.2%.
Valuation Metrics
Market Cap
$66.78M
Enterprise Value
$18.69M
P/E Ratio
14.3x
PEG Ratio
-0.2x
Price/Sales
72.8x
Growth & Margins
Revenue Growth (YoY)
+112.1%
Gross Margin
+89.0%
Operating Margin
-3,360.9%
Net Margin
+75.8%
EPS Growth
+7.7%
Financial Health
Cash/Price Ratio
+79.0%
Current Ratio
4.9x
Debt/Equity
0.7x
ROE
-33.2%
ROA
-14.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Rafael Holdings Inc. (RFL) Business Model
About Rafael Holdings Inc.
What They Do
Invests in healthcare and real estate.
Business Model
The company operates as a holding entity, investing in biopharmaceutical ventures and managing a portfolio of commercial real estate properties. It generates revenue through its investments in innovative therapies for cancer and metabolic diseases, as well as from leasing office buildings, primarily in Newark, New Jersey.
Additional Information
Rafael Holdings balances its real estate stability with high-growth healthcare opportunities, providing investors with exposure to both tangible assets and cutting-edge medical advancements. This diversified approach positions the company uniquely within the market, allowing it to leverage resources across different sectors.
Company Information
Sector
Real Estate
Industry
Real Estate Services
Employees
28
CEO
Mr. Howard S. Jonas
Country
United States
IPO Year
2018
Website
www.rafaelholdings.comRafael Holdings Inc. (RFL) Latest News & Analysis
Latest News
Quick Summary
Cyclo Therapeutics' Phase 3 trial for Trappsol® Cyclo™ in Niemann-Pick Disease Type C1 continues after positive review by the Data Monitoring Committee for safety and efficacy.
Why It Matters
Cyclo Therapeutics' trial progress signals potential advancements in treatment for Niemann-Pick Disease, which could enhance company valuation and attract investor interest in biotech innovation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rafael Holdings, Inc. announced the passing of Lead Independent Director Stephen Greenberg and appointed Alan Grayson to the Board. Markus Sieger will chair the Audit Committee and serve as Lead Independent Director.
Why It Matters
Leadership changes can impact company strategy and governance, affecting investor confidence and stock performance. New board members may influence future decisions and direction.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rafael Holdings reported positive preliminary results from a Phase 3 study of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1, showing 7 of 9 patients stabilized or improved after 48 weeks.
Why It Matters
Positive results from the NPC1 treatment study could enhance Rafael Holdings' market position and investor confidence, potentially impacting stock performance and future funding opportunities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rafael Holdings, Inc. announced that its subsidiary, Cyclo Therapeutics, will present two abstracts on Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 at ICIEM in Kyoto, Japan, from September 2-6, 2025.
Why It Matters
Rafael Holdings' presentation at a major medical congress highlights progress in a key treatment, potentially boosting investor confidence and impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rafael Holdings, Inc. (NYSE: RFL) announced its financial results for Q3 and the first nine months of FY 2025, ending on April 30, 2025.
Why It Matters
Rafael Holdings' quarterly financial results can signal company performance trends, affecting stock valuation, investor confidence, and potential market movements.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rafael Holdings closed a $25 million rights offering, raising $4 million by selling 3.1 million shares at $1.28 each. CEO Howard Jonas will purchase unsubscribed shares for $20.99 million.
Why It Matters
The successful completion of Rafael Holdings' $25 million rights offering and CEO's backing indicates confidence in the company, potentially boosting investor sentiment and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About RFL Stock
What is Rafael Holdings Inc.'s (RFL) stock forecast for 2026?
Analyst forecasts for Rafael Holdings Inc. (RFL) are not currently available. The stock is trading at $1.29.
Is RFL stock a good investment in 2026?
Analyst ratings for RFL are not currently available. The stock is currently trading at $1.29. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RFL stock?
Price predictions from Wall Street analysts for RFL are not currently available. The stock is trading at $1.29.
What is Rafael Holdings Inc.'s business model?
The company operates as a holding entity, investing in biopharmaceutical ventures and managing a portfolio of commercial real estate properties. It generates revenue through its investments in innovative therapies for cancer and metabolic diseases, as well as from leasing office buildings, primarily in Newark, New Jersey.
What is the highest forecasted price for RFL Rafael Holdings Inc.?
Price targets from Wall Street analysts for RFL are not currently available. The stock is trading at $1.29.
What is the lowest forecasted price for RFL Rafael Holdings Inc.?
Price targets from Wall Street analysts for RFL are not currently available. The stock is trading at $1.29.
What is the overall RFL consensus from analysts for Rafael Holdings Inc.?
Analyst ratings for RFL are not currently available. The stock is trading at $1.29.
How accurate are RFL stock price projections?
Stock price projections, including those for Rafael Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 8, 2025 4:40 PM UTC